Jefferies Financial Group Inc. Bei Gene, Ltd. Transaction History

Jefferies Financial Group Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$175.1 - $226.71 $157,590 - $204,039	900 Added 45.0%	2,900 $657,000
Q4 2024 Feb 14, 2025	BUY	$174.72 - $246.04 $349,440 - $492,080	2,000 New	2,000 $369,000
Q1 2024 May 13, 2024	SELL	$141.8 - $181.47 $5.38 Million - $6.89 Million	-37,957 Reduced 82.52%	8,043 $1.26 Million
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $8.27 Million - $10.4 Million	46,000 New	46,000 $8.27 Million

297

32.1M

146K

140K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.